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Malaria in pregnancy: challenges for control and the need for 
urgent action 
Malaria in pregnancy has a devastating eﬀ ect on 
the health of mothers and their babies, and is an 
important cause of maternal and infant mortality and 
morbidity.1 The greatest eﬀ ect of malaria in pregnancy 
is concentrated in sub-Saharan Africa and is associated 
with Plasmodium falciparum infection. However, 
pregnant women are also at risk of Plasmodium vivax 
malaria. Although its burden seems to be lower than 
that of P falciparum, P vivax malaria is still associated with 
harmful consequences for maternal and infant health.2 
WHO promotes three strategies for the control of 
P falciparum infection in pregnancy in Africa, which 
include provision of intermittent preventive treatment 
for malaria in pregnancy (IPTp) with sulfadoxine-
pyrimethamine (SP), use of insecticide-treated nets 
(ITNs), and prompt diagnosis and treatment of 
conﬁ rmed infections.  Unlike in stable transmission 
areas, no global recommendations currently exist for the 
prevention of malaria in pregnancy in low-transmission 
areas or those P vivax predominates. 
In 2000, under the Roll Back Malaria Partnership, 
Abuja targets were set for at least 60% of pregnant 
women who are at risk of malaria to have access to 
antimalarial chemoprophylaxis or IPTp-SP by 2005, and 
at least 80% use of ITNs by 2010.3 These targets were 
subsequently reset with even more ambition to 100% 
use of both interventions by 2015. However, coverage 
estimates for IPTp-SP and long-lasting ITNs in the sub-
Saharan region have increased only modestly in past 
years, reaching about 21% coverage for two doses of 
IPTp-SP and 41% for ITNs on average in 2010.4 Problems 
with the delivery of control interventions for malaria in 
pregnancy are linked to weaknesses within the health 
system, such as insuﬃ  cient resources, inadequate or 
poorly trained staﬀ , and ineﬀ ective procurement and 
supply chain management of SP and ITNs. In 2012, 
WHO updated its policy for IPTp-SP, recommending an 
increase in the number of doses of SP to be administered 
at each scheduled antenatal care visit, starting as early 
as possible in the second trimester.5 Countries currently 
face many obstacles in the scale-up of the provision of 
IPTp-SP, including inconsistencies between the WHO 
guidelines and national policies, which have increased 
the number of missed opportunities for control of 
malaria in pregnancy. 
Accordingly, the main challenge for reducing the 
burden of malaria in pregnancy in Africa is related to 
the adoption of national policies that incorporate WHO 
guidance, and eﬀ ective implementation and scaling-up 
of programmes. Health systems need to be strengthened 
to successfully provide interventions for the prevention 
and treatment of malaria in pregnancy as part of the 
platform for antenatal care. Innovative approaches to 
increase demand must be explored so more women 
can be reached and earlier in pregnancy. Harmonisation 
of policies between malaria control and reproductive, 
maternal, newborn, and child health programmes 
is urgently needed and will be crucial to meet global 
targets. Together, these programmes must address both 
supply and demand challenges and derive clear lessons 
from assessment of new approaches to the delivery of 
preventive strategies, such as maximisation of coverage 
through community-directed interventions delivered by 
community health workers.
Challenges for eﬀ ective prevention of malaria in 
pregnancy are increased in pregnant women living 
with HIV, especially in view of the fact that IPTp-SP 
is contraindicated for HIV-infected pregnant women 
receiving co-trimoxazole prophylaxis to prevent 
opportunistic infections.6 This has several implications 
for health systems: ﬁ rst, it tends to create confusion 
among front-line health workers, sometimes leading to 
both drugs being given and, second, because of frequent 
stock-outs of HIV screening tests, women often do not 
receive any preventive drugs. Additionally, suitable 
approaches for the prevention of malaria infection 
in the ﬁ rst trimester of gestation, for both pregnant 
women living with HIV and those not infected, have yet 
to be identiﬁ ed. None of the currently recommended 
antimalarial drugs can be given in this critical period 
because of safety risks for the embryo.7 Thus, malaria 
protection in the ﬁ rst trimester relies mostly on vector 
control measures, mainly ITNs that are usually provided 
later in pregnancy. 
Research priorities should include the assessment of 
innovative programming to address the low uptake 
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of preventive interventions for malaria in pregnancy; 
ensuring eﬀ ective protection in particularly susceptible 
groups such as HIV-infected pregnant women; 
improving of malaria control in the ﬁ rst trimester of 
gestation; and evaluation of alternative antimalarials 
to replace SP because of increasing resistance to this 
antimalarial drug.8,9 Research is also needed with 
respect to the malaria elimination agenda, including 
identiﬁ cation of the most suitable strategies for control 
of malaria in pregnancy and for radical cure of P vivax 
and P falciparum infections in low-transmission settings 
that are on track towards malaria elimination. 
Targets for malaria control in pregnancy are far 
from being reached, despite global gains in malaria 
investment during the past decade, which have resulted 
in substantial overall reductions in deaths from malaria 
and the existence of highly cost-eﬀ ective tools for 
malaria in pregnancy that have potential to save many 
maternal and neonatal lives. The challenges for eﬀ ective 
control of malaria in pregnancy need a multidisciplinary 
approach that includes the coordination and integration 
of programmes for malaria and maternal and 
reproductive health, increased provision of resources 
to provide the best antenatal care, and investigation 
of the role of new and innovative delivery approaches 
to maximise coverage of interventions to prevent 
malaria. To have an immediate eﬀ ect, a global call to 
action is urgently needed to increase national coverage 
and protect mothers and babies from the devastating 
consequences of malaria in pregnancy. 
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